Tag: Alzheimer’s
PET Changes Similar for Alzheimer Disease, Down Syndrome
No difference seen in global PET amyloid burden between asymptomatic with Down syndrome, asymptomatic mutation carriers
Study Explores Impact of FDA Approval of Aducanumab on Trial Participation
Individuals who were independently aware of the FDA decision demonstrated reduced willingness to participate
Lecanemab Reduced Markers of Amyloid in Early Alzheimer Disease
Moderately less decline seen in cognition and function at 18 months with lecanemab versus placebo
Second Death in Trial of Experimental Alzheimer Drug Raising Concerns
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds
Telmisartan Linked to Reduced Risk for Alzheimer Disease in Black Patients
African American-specific beneficial effects of telmisartan identified in Mendelian randomization analysis
Phosphodiesterase-5 Inhibitors Not Tied to Alzheimer Disease Risk
No evidence seen for reduced risk for Alzheimer disease and related dementia across four separate analytic approaches
New Model Predicts Five-Year Alzheimer Dementia Risk
Model includes demographic information, brain imaging test results, and genetic biomarkers
AAO: Normal-Tension Glaucoma Tied to Higher Alzheimer Disease Risk
Authors say people with normal-tension glaucoma should be screened for Alzheimer disease
One in Three Family Caregivers for Alzheimer Disease Patients Has Depression
Authors say the health of family caregivers should be monitored in clinical practices
Hospital-Treated Infections Earlier in Life Tied to Alzheimer, Parkinson Disease Risk
Association found for Alzheimer and Parkinson disease cases diagnosed before 60 years of age
